- $47.75m
- -$30.82m
- $24.35m
- 24
- 47
- 18
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.61 | ||
| Price to Tang. Book | 0.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.91% | ||
| Return on Equity | -62.26% | ||
| Operating Margin | -296.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 15 | 1.12 | 15.22 | 24.35 | 25.02 | 27.7 | 3.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 16th, 2007
- Public Since
- June 26th, 2018
- No. of Shareholders
- 84
- No. of Employees
- 70
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 24,614,834
- Address
- 17383 Sunset Avenue, Suite A250, PACIFIC PALISADES, 90272
- Web
- https://aadibio.com/
- Phone
- +1 4244738055
- Contact
- Scott Giacobello
- Auditors
- BDO USA, P.C.
Upcoming Events for AADI
Q4 2024 Aadi Bioscience Inc Earnings Release
Similar to AADI
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Altamira Therapeutics
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Aadi Bioscience share price?
As of Today at 19:00 UTC, shares in Aadi Bioscience are trading at $1.94. This share price information is delayed by 15 minutes.
How has the Aadi Bioscience share price performed this year?
Shares in Aadi Bioscience last closed at $1.94 and the price had moved by -55.61% over the past 365 days. In terms of relative price strength the Aadi Bioscience share price has underperformed the S&P500 Index by -66.74% over the past year.
What are the analyst and broker recommendations for Aadi Bioscience?
The overall consensus recommendation for Aadi Bioscience is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aadi Bioscience dividend yield?
Aadi Bioscience does not currently pay a dividend.
Does Aadi Bioscience pay a dividend?
Aadi Bioscience does not currently pay a dividend.
When does Aadi Bioscience next pay dividends?
Aadi Bioscience does not currently pay a dividend.
How do I buy Aadi Bioscience shares?
To buy shares in Aadi Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aadi Bioscience?
As of the previous close price of $1.94, shares in Aadi Bioscience had a market capitalisation of $47.75m.
Where are Aadi Bioscience shares listed?
Here are the trading details for Aadi Bioscience:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AADI
What kind of share is Aadi Bioscience?
Based on an overall assessment of its quality, value and momentum Aadi Bioscience is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aadi Bioscience share price forecast for 2024?
The analyst consensus target price for shares in Aadi Bioscience is $1.63. That is 15.98% below the last closing price of $1.94.
Analysts covering Aadi Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -$2.02 for the next financial year.
Find out moreWhat is the trend in the Aadi Bioscience share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aadi Bioscience. Over the past six months, its share price has underperformed the S&P500 Index by -17.61%.
As of the last closing price of $1.94, shares in Aadi Bioscience were trading +7.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aadi Bioscience PE Ratio?
The Aadi Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aadi Bioscience?
We do not have data on Aadi Bioscience's directors